. 31. Lau WY, Kennedy AS, Kim YH, Lai HK, Lee RC, et al. Patient choice and activity preparing guide for selective internal radiotherapy with yttrium-90 resin microspheres. Int J Radiat Oncol Biol Phys 82: 401407. 32. Gil-Alzugaray B, Chopitea A, Inarrairaegui M, Bilbao JI, Rodriguez-Fraile M, ~ et al. Prognostic components and prevention of radioembolization-induced liver disease. Hepatology 57: 10781087. 33. Hoffman MA, Rubin JI, Vinceguerra VP, Nowakowski FS, Warner RR Serious coagulopathy following 90Y microsphere administration: resemblance to the Kasabach-Merritt syndrome. J Vasc Interv 1655472 Radiol 19: 10991102. 34. Yang CW, Yen HH, Su WW, Chen YY, Soon MS Profound transient thrombocytopenia related to 90Yttrium microsphere therapy for inoperable hepatoma. South Med J 103: 12641268. 35. Leung TW, Lau WY, Ho SK, Ward SC, Chow JH, et al. Radiation pneumonitis following selective internal radiation remedy with intraarterial yttrium-90 microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys 33: inhibitor 919924. 36. Erhardt A, Kolligs F, Dollinger M, Schott E, Wege H, et al. Sorafenib plus TACE for the therapy of sophisticated hepatocellular carcinoma: final final results with the SOCRATES trial. J Hepatol 54: S35, abstract 79. 37. Wang JH, Changchien CS, Hu TH, Lee CM, Kee KM, et al. The efficacy of remedy schedules based on Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma – Survival analysis of 3892 inhibitor individuals. Eur J Cancer 44: 10001006. 38. Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, et al. Efficacy and security of sorafenib in sufferers with advanced hepatocellular carcinoma: Subanalysis of a phase III trial. J Hepatol 57: 821829. 12 ~~ ~~.. 31. Lau WY, Kennedy AS, Kim YH, Lai HK, Lee RC, et al. Patient selection and activity preparing guide for selective internal radiotherapy with yttrium-90 resin microspheres. Int J Radiat Oncol Biol Phys 82: 401407. 32. Gil-Alzugaray B, Chopitea A, Inarrairaegui M, Bilbao JI, Rodriguez-Fraile M, ~ et al. Prognostic aspects and prevention of radioembolization-induced liver disease. Hepatology 57: 10781087. 33. Hoffman MA, Rubin JI, Vinceguerra VP, Nowakowski FS, Warner RR Severe coagulopathy after 90Y microsphere administration: resemblance to the Kasabach-Merritt syndrome. J Vasc Interv 1655472 Radiol 19: 10991102. 34. Yang CW, Yen HH, Su WW, Chen YY, Quickly MS Profound transient thrombocytopenia related to 90Yttrium microsphere therapy for inoperable hepatoma. South Med J 103: 12641268. 35. Leung TW, Lau WY, Ho SK, Ward SC, Chow JH, et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial yttrium-90 microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys 33: 919924. 36. Erhardt A, Kolligs F, Dollinger M, Schott E, Wege H, et al. Sorafenib plus TACE for the therapy of advanced hepatocellular carcinoma: final outcomes with the SOCRATES trial. J Hepatol 54: S35, abstract 79. 37. Wang JH, Changchien CS, Hu TH, Lee CM, Kee KM, et al. The efficacy of treatment schedules as outlined by Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma – Survival evaluation of 3892 individuals. Eur J Cancer 44: 10001006. 38. Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, et al. Efficacy and safety of sorafenib in sufferers with sophisticated hepatocellular carcinoma: Subanalysis of a phase III trial. J Hepatol 57: 821829. 12 ~~ ~~.
